Loading clinical trials...
Loading clinical trials...
A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)
Conditions
Interventions
High dose ANAVEX2-73
Mid dose ANAVEX2-73
+1 more
Locations
54
Australia
Central Coast Neurosciences Research
Central Coast, New South Wales, Australia
Hornsby (Northern Sydney Health)
Hornsby, New South Wales, Australia
KaRa MINDS
Macquarie Park, New South Wales, Australia
St Vincent Hospital Sydney
Sydney, New South Wales, Australia
University of Sydney
Sydney, New South Wales, Australia
Gold Coast Memory Disorders Clinic
Southport, Quennsland, Australia
Start Date
July 3, 2018
Primary Completion Date
June 30, 2022
Completion Date
June 30, 2022
Last Updated
July 14, 2022
NCT07545473
NCT04570085
NCT07531732
NCT07290387
NCT06501495
NCT06121544
Lead Sponsor
Anavex Life Sciences Corp.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions